Search research articles
Contact Us
Filters
Showing results (11-20 of 35) with videos related to
Page
of 4
Sort By:
Cancer Research
|
August 15, 2008
Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo
Yihong Zhang, Paula J Kaplan-Lefko, Karen Rex, et al.
Molecular Cancer Therapeutics
|
October 5, 2019
Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma
May Elbanna, Ashley R Orillion, Nur P Damayanti, et al.
Molecular Cancer Research : MCR
|
July 29, 2017
Selective MET Kinase Inhibition in MET-Dependent Glioma Models Alters Gene Expression and Induces Tumor Plasticity
Corina N A M van den Heuvel, Anna C Navis, Tessa de Bitter, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 19, 2012
Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors
Christiane M Bode, Alessandro A Boezio, Brian K Albrecht, et al.
The Journal of Biological Chemistry
|
December 7, 2007
c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations
Steven F Bellon, Paula Kaplan-Lefko, Yajing Yang, et al.
Cancer Immunology Research
|
July 3, 2026
Coordinated immune activation following KRAS inhibition in syngeneic models reveals molecular pathways that potentiate and limit antitumor immunity
Daniel R Lu, Tao Osgood, Shining Ma, et al.
Cancer Research
|
February 3, 2006
Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors
Teresa Burgess, Angela Coxon, Susanne Meyer, et al.
Molecular Cancer Therapeutics
|
May 20, 2016
In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models
Paul E Hughes, Karen Rex, Sean Caenepeel, et al.
Journal of Medicinal Chemistry
|
June 17, 2008
Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458)
Longbin Liu, Aaron Siegmund, Ning Xi, et al.
Journal of Medicinal Chemistry
|
February 21, 2015
Discovery of potent and selective 8-fluorotriazolopyridine c-Met inhibitors
Emily A Peterson, Yohannes Teffera, Brian K Albrecht, et al.
Page
of 4
Search research articles
Search
Showing results (11-20 of 35) with videos related to
Sort By:
Page
of 4
Cancer Research
|
August 15, 2008
Identification of a novel recepteur d'origine nantais/c-met small-molecule kinase inhibitor with antitumor activity in vivo
Yihong Zhang, Paula J Kaplan-Lefko, Karen Rex, et al.
Molecular Cancer Therapeutics
|
October 5, 2019
Dual Inhibition of Angiopoietin-TIE2 and MET Alters the Tumor Microenvironment and Prolongs Survival in a Metastatic Model of Renal Cell Carcinoma
May Elbanna, Ashley R Orillion, Nur P Damayanti, et al.
Molecular Cancer Research : MCR
|
July 29, 2017
Selective MET Kinase Inhibition in MET-Dependent Glioma Models Alters Gene Expression and Induces Tumor Plasticity
Corina N A M van den Heuvel, Anna C Navis, Tessa de Bitter, et al.
Bioorganic & Medicinal Chemistry Letters
|
May 19, 2012
Discovery and optimization of a potent and selective triazolopyridinone series of c-Met inhibitors
Christiane M Bode, Alessandro A Boezio, Brian K Albrecht, et al.
The Journal of Biological Chemistry
|
December 7, 2007
c-Met inhibitors with novel binding mode show activity against several hereditary papillary renal cell carcinoma-related mutations
Steven F Bellon, Paula Kaplan-Lefko, Yajing Yang, et al.
Cancer Immunology Research
|
July 3, 2026
Coordinated immune activation following KRAS inhibition in syngeneic models reveals molecular pathways that potentiate and limit antitumor immunity
Daniel R Lu, Tao Osgood, Shining Ma, et al.
Cancer Research
|
February 3, 2006
Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c-Met-dependent human tumors
Teresa Burgess, Angela Coxon, Susanne Meyer, et al.
Molecular Cancer Therapeutics
|
May 20, 2016
In Vitro and In Vivo Activity of AMG 337, a Potent and Selective MET Kinase Inhibitor, in MET-Dependent Cancer Models
Paul E Hughes, Karen Rex, Sean Caenepeel, et al.
Journal of Medicinal Chemistry
|
June 17, 2008
Discovery of a potent, selective, and orally bioavailable c-Met inhibitor: 1-(2-hydroxy-2-methylpropyl)-N-(5-(7-methoxyquinolin-4-yloxy)pyridin-2-yl)-5-methyl-3-oxo-2-phenyl-2,3-dihydro-1H-pyrazole-4-carboxamide (AMG 458)
Longbin Liu, Aaron Siegmund, Ning Xi, et al.
Journal of Medicinal Chemistry
|
February 21, 2015
Discovery of potent and selective 8-fluorotriazolopyridine c-Met inhibitors
Emily A Peterson, Yohannes Teffera, Brian K Albrecht, et al.
Page
of 4